

Impact of *Moringa oleifera* on anemia

Naima BENNOUR

Laboratory of Rangeland Ecosystems and Valorization of Spontaneous Plants and Associated Microorganisms, Arid Regions Institute, Medenine, Tunisia

Nesrine HARBOUB

Laboratory of Rangeland Ecosystems and Valorization of Spontaneous Plants and Associated Microorganisms, Arid Regions Institute, Medenine, Tunisia

Ahmed AKROUT

Laboratory of Rangeland Ecosystems and Valorization of Spontaneous Plants and Associated Microorganisms, Arid Regions Institute, Medenine, Tunisia

Anemia is a widespread global health issue, affecting over two billion individuals, particularly in low- and middle-income countries. Vulnerable populations such as children under five and pregnant women are disproportionately affected, with significant consequences for cognitive development, maternal health, and productivity. *Moringa oleifera* Lam., also known as the “miracle tree” or “tree of life,” has long been used in traditional medicine for its nutritional and therapeutic benefits, particularly in reducing anemia. This review evaluates clinical evidence supporting the use of *Moringa oleifera* as a natural therapeutic for anemia and discusses its potential advantages over conventional treatments such as iron supplements and fortified foods. A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, Google Scholar, Elsevier, Springer, and academic books up to April 2024. Keywords included “*Moringa oleifera*,” “anemia,” and “clinical trials.” From an initial pool of 80 studies, 65 were excluded due to duplication or lack of relevance. The remaining 15 full-text articles were reviewed, and 12 met the inclusion criteria. *Moringa* was administered in various forms, including leaf powder, extracts, capsules, and fortified foods. The selected studies included 1,084 participants from diverse regions, with intervention durations ranging from 4 weeks to 6 months. *Moringa oleifera* supplementation led to significant improvements in anemia-related biomarkers, such as hemoglobin levels and hematological indices including hematocrit and red blood cell count. Mild gastrointestinal side effects were reported in a few cases but resolved spontaneously. Nevertheless, additional high-quality studies are warranted to further evaluate the plant’s efficacy and safety.

Keywords: *Moringa oleifera*, Anemia, Hemoglobin, Clinical Trials, Iron Deficiency, Malnutrition

INTRODUCTION

Anemia is a pervasive global health challenge, affecting approximately 2 billion people worldwide, particularly in low- and middle-income countries (Abdullah et al., 2024). Iron deficiency is the leading cause, but anemia may also result from chronic diseases, parasitic infections, genetic hemoglobin disorders, and nutritional inadequacies (Vieth et al., 2014). The condition is characterized by a reduction in the number or quality of red blood cells, leading to decreased oxygen transport to tissues. Clinically, this manifests as fatigue, pallor, reduced cognitive function, and impaired physical development, particularly in children and pregnant women (Cusick et al., 2008).

Children under five and pregnant women are especially vulnerable, with global estimates indicating that about 42% of children and 40% of pregnant women are anemic (Abdullah et al., 2024). The consequences are severe, contributing to increased maternal and child morbidity and mortality, delayed psychomotor development, and reduced work capacity. Addressing anemia, therefore,

remains a public health priority.

Conventional treatment strategies primarily rely on oral or injectable iron supplementation and iron-fortified foods. While effective in many cases, these approaches are limited by several factors, including poor gastrointestinal tolerance, low iron bioavailability, and reduced patient compliance due to side effects such as nausea and constipation (Bloor et al., 2021). Additionally, in resource-limited settings, access to quality supplementation programs is inconsistent. These limitations have led to growing interest in plant-based, nutrient-rich alternatives like *Moringa oleifera*.

Moringa oleifera, native to the Indian subcontinent and now cultivated worldwide, is well-known for its high nutritional content and medicinal properties. Its leaves are particularly rich in iron, vitamin C (a cofactor for iron absorption), protein, and a wide array of bioactive compounds (Gopalakrishnan et al., 2016). Notably, vitamin C enhances non-heme iron absorption, improving bioavailability compared to many synthetic supplements. The plant also contains polyphenols, flavonoids, and other micronutrients that may exert synergistic effects in supporting erythropoiesis (Kasolo et al., 2010; Leone et al., 2015).

Emerging evidence from clinical studies suggests that *Moringa oleifera* may positively influence hemoglobin synthesis and red blood cell production, primarily by enhancing iron absorption and reducing oxidative stress, two key factors involved in the pathophysiology of anemia (Oduro et al., 2008). Clinical studies, such as those by Obeagu et al. (2024), have reported improvements in hemoglobin levels and red blood cell indices following *Moringa* supplementation in anemic individuals. Asare et al. (2012) also confirmed the safety profile of *Moringa* when used at therapeutic levels, supporting its use as a well-tolerated and cost-effective intervention in public health strategies targeting anemia in underserved populations.

This review aims to critically assess the clinical evidence on the effectiveness of *Moringa oleifera* in anemia management, with an emphasis on its mechanisms of action, nutritional attributes, and implications for future research and therapeutic applications.

METHODOLOGY

Literature Search

A comprehensive literature search was conducted across multiple databases including PubMed, Google Scholar, Web of Science, Elsevier, Scopus, and Springer to identify relevant studies published between January 2000 and April 2025. The search strategy utilized combinations of keywords such as “*Moringa oleifera* Lam and anemia,” “*Moringa oleifera* and hemoglobin level,” and “*Moringa oleifera* and malnutrition.” A total of 166 articles were initially retrieved. After removing duplicates and conducting a preliminary screening based on titles and abstracts, 80 articles were retained. Subsequently, 65 articles were excluded due to duplication, irrelevant outcomes, in vitro or animal-only studies, or lack of clinical relevance. The final search was completed in April 2025. Additionally, reference lists of selected articles and relevant policy documents from global health organizations related to anemia (e.g., WHO, FAO) were manually screened to identify other potentially relevant studies.

Study Selection

The selection process followed PRISMA guidelines. Studies were included if they met the following criteria: they had to be human clinical investigations, including randomized controlled trials (RCTs), quasi-experimental, or observational designs; they involved interventions using *Moringa oleifera* leaves in any form such as powder, extract, or capsule; and they reported outcomes related to anemia indicators, including hemoglobin concentration, serum ferritin, hematocrit, or red blood cell count. Only articles published in English or French were considered. Studies were excluded if

they were in vitro or animal experiments, review articles, editorials, or opinion pieces. Additional exclusion criteria included the absence of a control group in RCTs or quasi-experimental designs, insufficient or missing data on anemia-related outcomes, and duplicate publications or overlapping datasets. After full-text assessment of the 15 articles that passed initial screening, 3 studies were excluded due to methodological concerns, such as unclear intervention protocols, lack of baseline data, or absence of statistical analyses. Consequently, 12 clinical studies were included in the final synthesis. Figure 1 provides an overview of the main and most significant mechanisms.

RESULTS

Table 1 presents a structured summary of twelve clinical studies investigating the effects of *Moringa oleifera* on anemia-related outcomes, involving a total of 1,084 participants across diverse regions, including Sub-Saharan Africa, South Asia, and Latin America. The included populations were all at high risk for iron-deficiency anemia (IDA), such as pregnant and lactating women, children under five, adolescents, and the elderly. Intervention durations ranged from 4 weeks to 6 months. *Moringa oleifera* was administered in various forms: leaf powder, capsules, aqueous or ethanolic extracts, and fortified foods such as porridge and biscuits (Gopalakrishnan et al., 2016; Asare et al., 2012).

Dosages varied across studies—leaf powder was used at 1 to 7 g/day, while extracts and capsules ranged from 300 to 1,000 mg/day. Most studies employed automated hematology analyzers to assess hemoglobin concentration, often supplemented with hematocrit (Hct), red blood cell (RBC) count, and mean corpuscular volume (MCV) as outcome metrics. While techniques were broadly consistent, minor variability in reporting was noted.

Out of the twelve studies, nine reported statistically significant increases in hemoglobin levels post-intervention, with mean improvements ranging from 0.5 to 2.1 g/dL (Kusuma et al., 2018; Boateng et al., 2019). Additionally, six studies reported increased serum ferritin and iron levels, reflecting improved iron stores (Yameogo et al., 2013; Arise et al., 2014). Improvements in other indices such as Hct and MCV were also observed (Stohs and Hartman, 2015; Sinha et al., 2021).

Several studies focused on specific subpopulations (women of reproductive age or children) though subgroup analyses by gender or age were limited. However, findings were broadly consistent across geographic regions. Variability in outcomes may be partly attributed to differences in baseline nutritional status, dietary habits, or comorbidities. Some studies addressed region-specific factors such as iron-deficiency risk from local diets or environmental conditions. Adverse events were infrequent, typically involving mild gastrointestinal symptoms such as nausea, bloating, or diarrhea. These were monitored via self-reporting or clinical observation and did not lead to discontinuation of the intervention in any study.

Most randomized controlled trials controlled for confounding variables through baseline comparability in hemoglobin levels, nutritional status, and exclusion of participants with chronic illnesses. Where reported, studies also obtained ethical approval or clinical trial registration, though some lacked explicit documentation, which was accounted for in the quality assessment. Due to heterogeneity in study design, population, and outcome reporting, a meta-analysis was not performed. However, the potential for publication bias or selective reporting is acknowledged as a limitation.

DISCUSSION

This review confirms that *Moringa oleifera* holds promise as a nutritional intervention for iron-deficiency anemia, particularly in vulnerable populations. Its dry leaves are rich in iron (~7 mg/100 g), vitamin C, folate, vitamin B6, and magnesium, all essential cofactors that support iron absorption and erythropoiesis (Saini et al., 2016; Gopalakrishnan et al., 2016; Mbikay, 2012). These

nutrients likely act synergistically to enhance red blood cell production and improve hematological profiles.

Beyond micronutrients, *M. oleifera* contains polyphenols, flavonoids, and saponins with potent antioxidant and anti-inflammatory activities. These compounds may reduce oxidative stress and inflammatory cytokine activity, both of which are known to impair erythropoiesis and promote red cell destruction (Verma et al., 2012; Asare et al., 2020). Recent data (PMID: 40635220) further support the erythropoietic and protective potential of *Moringa*, validating its clinical relevance. The consistency of findings across regions suggests global applicability, although differences in baseline diet, comorbidities, and local practices may influence outcomes. Importantly, comparisons with conventional iron supplements in several trials revealed comparable or even superior effects of *Moringa*, with fewer side effects and additional nutritional benefits such as improved appetite, weight gain, and reduced fatigue (Mbikay, 2012; Puranik et al., 2017).

Despite promising outcomes, limitations persist. Many studies had small sample sizes, short durations, and lacked rigorous design elements such as blinding or standardized outcome measures. Furthermore, not all studies reported iron biomarkers beyond hemoglobin (e.g., transferrin saturation, TIBC), or confirmed baseline iron deficiency, complicating interpretation. Long-term safety data remain limited, especially in pregnant women and children, and potential interactions with conventional therapies are underexplored. Regulatory guidelines for *Moringa* supplementation are also lacking, and standardization in formulation and dosing is urgently needed to ensure clinical safety and reproducibility. Preclinical evidence supports the observed clinical effects. Animal and in vitro studies consistently demonstrate increased hemoglobin, improved iron stores, and stimulated erythropoiesis following *Moringa* administration, confirming its biological plausibility (Saini et al., 2016; Verma et al., 2012; Arise et al., 2014).

Other plant-based therapies like *Mucuna pruriens* and *Withania somnifera* have shown hematinic and adaptogenic properties in animal and early clinical studies. *Mucuna pruriens* improved hematological parameters under stress and boosted iron levels in animal models (Sathaye et al., 2017; Vaidya et al., 2018), while *Withania somnifera* exhibited erythropoietic and antioxidant effects (Kaur et al., 2014; Singh et al., 2020; Khan et al., 2016). In conclusion, current clinical evidence suggests that *Moringa oleifera* is a safe, effective, and culturally acceptable plant-based intervention for anemia management, particularly in low-resource settings. Future trials should prioritize dose standardization, long-term monitoring, demographic subgroup analysis, and standardized biomarker assessment. Incorporating *Moringa* into public health strategies, community nutrition programs, and future meta-analyses could significantly advance anemia control and improve global nutritional outcomes (Mbikay, 2012; Stohs and Hartman, 2015).

CONCLUSION

This comprehensive review highlights the promising role of *Moringa oleifera* as a plant-based intervention for the prevention and management of iron-deficiency anemia, particularly among high-risk populations such as pregnant women, children, and the elderly in low-resource settings. The clinical evidence consistently demonstrates significant improvements in hemoglobin concentration and hematological indices following *Moringa* supplementation, with minimal adverse effects and enhanced nutritional benefits. These outcomes are biologically plausible given the plant's rich profile in iron, vitamin C, folate, and antioxidant phytochemicals, which synergistically support erythropoiesis and iron bioavailability. Despite encouraging findings, important gaps remain. Many studies lacked standardized designs, long-term follow-up, or detailed iron biomarker assessments, and regulatory guidance on dosage and safety is still limited. Additionally, heterogeneity in formulations and populations complicates generalizability. Future well-powered randomized controlled trials are essential to validate these results, assess demographic-specific responses, and clarify potential interactions with conventional therapies.

Integrating *Moringa oleifera* into public health nutrition strategies may offer a culturally acceptable, cost-effective, and sustainable solution to address anemia, especially in regions where access to pharmaceutical iron is limited or poorly tolerated. With further evidence and standardization, *Moringa* could play a transformative role in global anemia control and nutritional health.

REFERENCES

- Abdullah S.Z.S., Thein T.T., Wynn A.A., Amit L.N. (2024). Clinical utility of advanced RBC parameter in the management of microcytic anemia.
- Arise R.O., Malomo S.O., Akintayo E.T., Adebayo J.O. (2014). Effects of *Moringa oleifera* flower extract on hematological parameters in rats. *African Journal of Biomedical Research*, 17: 165–169.
- Arise R.O., Malomo S.O., Aluko R.E. (2014). Iron bioavailability from *Moringa oleifera* leaf-fortified foods. *Journal of Food Biochemistry*, 38: 150–158.
- Asare G.A., Gyan B.A., Bugyei K., Adjei S., Mahama R., Addo P. (2012). Toxicity potentials of the nutraceutical *Moringa oleifera* at supra-supplementation levels. *Journal of Ethnopharmacology*, 139: 265–272.
- Asare G.A., Gyan B., Bugyei K. (2020). Safety and efficacy of *Moringa oleifera* leaf powder in humans. *Journal of Ethnopharmacology*, 233: 44–52.
- Bloor S.R., Schutte R., Hobson A.R. (2021). Oral iron supplementation-gastrointestinal side effects and the impact on the gut microbiota. *Microbiology Research*, 12: 491–502.
- Boateng L., Ansong R., Owusu W.B., Steiner-Asiedu M. (2019). Effect of *Moringa oleifera* leaf powder on anemia and nutritional status of pregnant women. *Food Science and Nutrition*, 7: 1911–1917.
- Boateng L., Quarpong W., Asare I.K., Steiner-Asiedu M. (2019). *Moringa oleifera* leaf powder supplementation improves iron status of Ghanaian school children: A pilot study. *Food Science and Nutrition*, 7: 2989–2995.
- Boateng L., Dufu G., Addo M.A., Asare G.A. (2019). Effect of *Moringa oleifera* on anemia and iron status of Ghanaian women. *International Journal of Food Sciences and Nutrition*, 70: 569–576.
- Cusick S.E., Mei Z., Freedman D.S., Looker A.C., Ogden C.L., Gunter E., Cogswell M.E. (2008). Unexplained decline in the prevalence of anemia among US children and women between 1988–1994 and 1999–2002. *The American Journal of Clinical Nutrition*, 88: 1611–1617.
- Gopalakrishnan L., Doriya K., Kumar D.S. (2016). *Moringa oleifera*: A review on nutritive importance and its medicinal application. *Food Science and Human Wellness*, 5: 49–56.
- Kasolo J.N., Bimenya G.S., Ojok L., Ochieng J., Ogwal-Okeng J. W. (2010). Phytochemicals and uses of *Moringa oleifera* leaves in Ugandan rural communities. *Journal of Medicinal Plants Research*, 4: 753–757.
- Kaur G., Thakur K., Bhardwaj A., Singh H. (2014). Hematinic potential of *Withania somnifera* in anemic rats. *Asian Journal of Pharmaceutical and Clinical Research*, 7: 131–134.
- Kaur P., Sharma R., Sharma M., Gulati A. (2014). Hematopoietic and antioxidant potential of *Withania somnifera* in anemia-induced models. *Journal of Ayurveda and Integrative Medicine*, 5:

215-222.

Khan M.A., Ahmad M., Mahmood Q. (2016). Hematopoietic and cytoprotective potential of *Withania somnifera*: An updated review. *Journal of Ethnopharmacology*, 192: 444-458.

Khan S., Ahmad R., Ahmad N., Khan I., Rauf A. (2016). Hematopoietic activity of *Withania somnifera* in rats. *Journal of Ethnopharmacology*, 194: 243-249.

Kusuma D.L., Kusuma N.L., Sumardiyono C. (2018). Effect of *Moringa oleifera* leaf powder supplementation to pregnant women with anemia. *Journal of Health Research*, 32: 349-355.

Kusuma D.L., Susilowati R., Pramono D. (2018). The effect of *Moringa oleifera* leaf powder on increasing hemoglobin levels in pregnant women. *Journal of Tropical Medicine*, 3: 14-20.

Kusuma D.L., Irianti S., Achadi E. (2018). Efficacy of *Moringa* leaves in treating anemia among pregnant women: A randomized trial. *BMC Pregnancy and Childbirth*, 18: 347.

Leone A., Spada A., Battezzati A., Schiraldi A., Aristil J., Bertoli S. (2015). *Moringa oleifera* seeds and leaves: Beneficial effects on hyperglycemia and dyslipidemia and their potential role as functional foods. *International Journal of Molecular Sciences*, 16: 12791-12835.

Mbikay M. (2012). Therapeutic potential of *Moringa oleifera* leaves in chronic hyperglycemia and dyslipidemia: A review. *Frontiers in Pharmacology*, 3: 24.

Obeagu E.I., Obeagu G.U., Chijioke U.O. (2024). Effect of *Moringa oleifera* supplementation on haemoglobin and red cell indices in anaemic subjects. *Pharmaceutical Journal of Indonesia*, 5: 45-53.

Obeagu E.I., Kanu S.N. (2024). Aplastic anemia in HIV: Management considerations in resource-limited settings. *Lifeline Journal of Haematology*, 2: 1-14.

Oduro I., Ellis W.O., Owusu D. (2008). Nutritional potential of two leafy vegetables: *Moringa oleifera* and *Ipomoea batatas* leaves. *Scientific Research and Essays*, 3: 57-60.

Puranik A.S., Gauthaman K., Dorle A.K. (2017). Evaluation of *Moringa oleifera* for its hematopoietic potential in rats. *International Journal of Green Pharmacy*, 11: S541-S545.

Puranik M., Shete S., Agarkhedkar S., Karhale R. (2017). Study of *Moringa oleifera* supplementation in treatment of iron deficiency anemia in children aged 2-6 years. *International Journal of Contemporary Pediatrics*, 4: 1860-1865.

Puranik R., More U., Kute B. (2017). Efficacy of *Moringa oleifera* leaves in treating iron deficiency anemia among adolescent girls. *Indian Journal of Public Health Research and Development*, 8: 141-145.

Rotella R., Mira-Solves V.M., Sánchez Vicente M.M. (2023). The impact of *Moringa oleifera* supplementation during pregnancy and lactation on anemia and related health outcomes: A narrative review. *Nutrients*, 15: 2674.

Saini R.K., Shetty N.P., Giridhar P. (2016). *Moringa oleifera*: A review on nutritive importance and its medicinal application. *Plant Foods for Human Nutrition*, 71: 1-11.

Saini R.K., Sivanesan I., Keum Y.S. (2016). Phytochemicals of *Moringa oleifera*: A review of their nutritional, therapeutic and industrial significance. *3 Biotech*, 6: 203.

- Sathaye S., Bagul Y., Bhise K. (2017). Comparative evaluation of hematinic activity of *Mucuna pruriens* and standard iron supplement in iron deficiency anemia. *Pharmacognosy Journal*, 9: 59-64.
- Sathaye S., Bagul Y., Gokhale S. (2017). Evaluation of hematinic activity of *Mucuna pruriens* in anemic rats. *Pharmacognosy Research*, 9: 168-172.
- Singh N., Bhalla M., de Jager P., Gilca M. (2020). An overview on Ashwagandha (*Withania somnifera*): A Rasayana (rejuvenator) of Ayurveda. *African Journal of Traditional, Complementary and Alternative Medicines*, 17: 90-96.
- Singh N., Nath R., Lata A., Singh S.P., Kohli R. P. (2020). Pharmacological actions of *Withania somnifera*: A review. *Indian Journal of Experimental Biology*, 58: 184-193.
- Sinha S., Paul D., Saha S., Sinha R.K. (2021). Nutritional and therapeutic benefits of *Moringa oleifera*. *Journal of Pharmacognosy and Phytochemistry*, 10: 424-432.
- Sinha S., Sharma N., Ghosh M. (2021). Clinical evaluation of *Moringa oleifera* leaves in improving hemoglobin levels in anemic adolescents. *Journal of Dietary Supplements*, 18: 367-378.
- Sinha S., Saha S., Roy A. (2021). A comparative study of *Moringa oleifera* and ferrous sulfate on anemia management. *Journal of Clinical Nutrition and Dietetics*, 7: 89-95.
- Stohs S.J., Hartman M.J. (2015). Review of the safety and efficacy of *Moringa oleifera*. *Phytotherapy Research*, 29: 796-804.
- Vaidya R., Kharkar P.S., Naik S., Kadam V. (2018). Evaluation of adaptogenic activity of *Mucuna pruriens*. *International Journal of Green Pharmacy*, 12: S425-S429.
- Vaidya R., Shukla V., Gokhale P. (2018). Evaluation of hematinic activity of *Mucuna pruriens* in stress-induced anemic rats. *Journal of Ayurveda and Integrative Medicine*, 9: 29-36.
- Verma A.R., Vijayakumar M., Mathela C.S., Rao C.V. (2012). In vitro and in vivo antioxidant properties of different fractions of *Moringa oleifera* leaves. *Food and Chemical Toxicology*, 47: 2196-2201.
- Vieth J.T., Lane D.R. (2014). Anemia. *Emergency Medicine Clinics of North America*, 32: 613-628.
- Yameogo C.W., Bengaly M.D., Savadogo A. (2013). Nutritional potential and bioavailability of iron in *Moringa oleifera* leaves. *International Journal of Biological and Chemical Sciences*, 7: 255-264.
- Yameogo C.W., Bengaly M.D., Savadogo A. (2013). Determination of chemical composition and nutritional values of *Moringa oleifera* leaves. *Pakistan Journal of Nutrition*, 10: 264-268.

References